Joining forces in high-throughput technologies will likely augment our success rate in their implementation and create a platform that researchers from other areas can benefit from as well. Coordinated efforts in microRNA profiling and functional assays helps us to save resources and increase informational output e.g. by recognizing tissue-specific expression modulation. The experience gained thus far shows that we can gain enormous synergies, thereby enhancing and accelerating our investigations of small RNA in a diverse range of human pathologies such as neurodegeneration (Aguzzi ), insulin resistance in skeletal muscle (Krützfeldt ), TDP-43 and FUS proteinopathies (Polymenidou), and growth, survival and insulin secretion in pancreatic tissue (Stoffel).
While the above fields are diverse, all participants need to develop the same type of know-how, methodologies, and technological platforms in order to reach their respective goals. Because of these synergies, this consortium is more valuable than the sum of its parts and has enabled progress that would not be achievable by any of the individual labs alone. We continue to be committed to maintaining an interdisciplinary, synergistic platform on small RNA research that will be highly accessible for other research groups in the future.